Is hormone optimization safe? For two decades, the standard answer to that question was a flat no, delivered as settled science. The position has softened as the evidence has matured. The honest answer in 2026 is that for symptomatic people, hormone therapy can be safe and appropriate when it is prescribed with a full clinical picture and unsafe when it is prescribed by anyone who skips the labs.

Key takeaways
  • The risk profile depends on timing, dose and monitoring, not on the category of treatment.
  • Symptoms alone are not a reason to prescribe. The Biomarker Audit exists so nobody prescribes against an unseen panel.
  • Branded, FDA-approved hormone therapy can be appropriate when properly managed. We never prescribe compounded GLP-1.
  • The prescribing clinician is licensed in your state and can name their reasoning in writing.

Why the reputation lagged the evidence

In the early 2000s the Women's Health Initiative reported risks from hormone therapy that made headlines and prescriptions fell sharply. The years since have produced a more nuanced read of that data. The trial population was older than typical menopause patients, the formulation differed from modern practice and the 2022 position statement of The North American Menopause Society concluded that for symptomatic women, hormone therapy remains the most effective treatment for vasomotor symptoms and is appropriate for many when individualized.

We are not going to oversell that correction. Hormone therapy is not for everyone and some risks remain. What has changed is the standard of care. It is an individualized decision, made with labs, that weighs your specific risk factors against your specific symptoms.

How we prescribe and what we require first

We do not prescribe hormones on a form and a video call. Every hormone protocol starts with the comprehensive Biomarker Audit. The panel includes Hs-CRP, Comprehensive Metabolic Panel, TSH With Reflex To Free T4, Fasting Insulin, Lipoprotein (A), Hemoglobin A1c (HbA1c), Lipid Panel, Standard, Apolipoprotein B (ApoB) and CBC (Includes Differential And Platelets), drawn at Quest Diagnostics.

The reason is that hormones do not act alone. Estrogen, progesterone, testosterone and thyroid interact with your cardiovascular markers, your metabolic health and your inflammation picture. Prescribing against an unseen panel is guesswork with a symptom checklist. Your clinician reviews the audit, then builds a protocol: bioidentical estrogen, progesterone or testosterone or thyroid support, matched to what your labs and your symptoms say together.

The prescribing clinician is licensed in your state. Medication is branded and FDA-approved, prescribed when clinically indicated to the pharmacy you choose. We never prescribe compounded GLP-1.

The safety questions worth asking any provider

These are the questions we would ask and the ones our protocols are built to answer.

  • What labs did you order before prescribing?
  • Who is monitoring the cardiovascular picture? Hormone therapy and cardiovascular risk interact, which is why our panel covers Apolipoprotein B (ApoB), Lipoprotein (A) and Hs-CRP.
  • What is the follow-up cadence? Ours is every 90 days, four times a year, with every result in your hands.
  • What happens when a dose is too high? Your clinician reviews it with you and adjusts.
  • Who profits if the dose climbs? With us, nobody. The fee is $299 a month whatever the dose and the pharmacy bills for the drug separately.

That last question is the one most providers cannot answer cleanly and it is the reason the flat-fee model exists. We take nothing on medication and the fee does not change with the dose.

GoodLife Health. Labs, clinician, medicine, platform, $299 a month: quarterly labs, your clinician, guided GLP-1s, your data in one place. Check eligibility.GoodLife Health. Your labs, your clinician, your medicine, your data. One place. Comprehensive labs every 90 days, a board-certified clinician, branded GLP-1s when indicated, and a platform that holds it all, $299 a month. Check your eligibility.

What the evidence does and does not say

The 2022 Menopause Society position statement is the clearest modern read on hormone therapy for symptomatic women and its conclusion is measured: hormone therapy remains the most effective treatment for vasomotor symptoms and is appropriate for many when individualized, with the decision shaped by age, time since menopause and personal risk factors.

For testosterone therapy in men, the trial evidence has also matured. The TRAVEL trial, published in the New England Journal of Medicine in 2023, followed more than 5,000 men with preexisting or high cardiovascular risk and found that testosterone replacement therapy did not increase major cardiac events compared with placebo. That is not a promise of safety for any individual. A clinician still rules out prostate cancer and uncontrolled heart failure before prescribing. It is an argument against the reflex that testosterone therapy is automatically dangerous.

Cardiovascular context matters here, because hormone therapy is never prescribed in isolation from the heart. Heart disease remains the leading cause of death in the United States, which is why our panel includes cardiometabolic markers.

Who should not pursue this

Hormone optimization is not a category to enter casually. Not everyone is accepted and the clinician decides whether hormone therapy is appropriate for you. If you are looking for a peptide protocol from a med spa, we are not that and we do not offer research peptides. If you want hormones as a fat-loss shortcut, this is not for you.

If instead your symptoms are real, your labs are in hand and you want a clinician who can name the reasoning in writing, the eligibility check is the first step. It takes a few minutes and a clinician reviews every application. The $598 for the first two months is held on your card, not charged and is charged only once a clinician accepts you. If the clinician cannot accept you, the hold is released and you are never charged. Once accepted, the first two months are charged and non-refundable.

Clinical note

Measure first, prescribe second, monitor quarterly.

Frequently Asked Questions

Is hormone optimization safe?

For symptomatic people, hormone therapy can be appropriate when a clinician prescribes it with a full clinical picture and monitors it. The 2022 position statement of The North American Menopause Society concluded that for symptomatic women, hormone therapy remains the most effective treatment for vasomotor symptoms when individualized. Risks remain and the decision is individual.

Do you prescribe bioidentical hormones?

Where clinically indicated, a clinician can prescribe FDA-approved hormone therapy to your pharmacy. We do not prescribe compounded medication.

What labs do you require before prescribing?

The Cardiometabolic Optimization Panel: Hs-CRP, Comprehensive Metabolic Panel, TSH With Reflex To Free T4, Fasting Insulin, Lipoprotein (A), Hemoglobin A1c (HbA1c), Lipid Panel, Standard, Apolipoprotein B (ApoB) and CBC (Includes Differential And Platelets), drawn at Quest Diagnostics. Hormone levels are ordered by the clinician when there is a reason and are billed by the lab at its own rates.

Who delivers the care?

A clinician licensed in your state.

Is this included in the $299 membership?

Yes. The membership fee covers the clinical relationship, the quarterly Biomarker Audit and any hormone protocol your clinician builds. Medication, when prescribed, is billed by your pharmacy separately at pharmacy cost.

Is hormone therapy the same as testosterone therapy for men?

No, they are different clinical questions with different evidence and different risk profiles. The same labs-first rule applies to both.

What if my symptoms change between audits?

You message the care team. The fee includes asynchronous messaging and your clinician can order follow-up labs or adjust the protocol between audits when the clinical picture calls for it.

What monitoring actually catches

Here is what the 90-day cadence changes in a hormone protocol.

It can show a dose that overshot. Your clinician decides what follows.

It can show a marker nobody prescribed for. The panel includes Apolipoprotein B (ApoB), so the clinician adjusting your protocol also sees the cardiovascular picture.

It can show a trend that ends the therapy. Some protocols turn out to be unnecessary once the underlying cause is treated. The panel lets your clinician review the protocol every 90 days and our fee does not depend on the prescription.

It builds a record over time. Lipids and insulin respond to hormonal changes over years and the quarterly record shows the trend.

That is the monitoring argument in practice.

One last thing

Measure first, prescribe second and monitor quarterly. That is the whole method.

Related Guides

References

  1. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. 2015. doi.org/10.1210/jc.2015-2236
  2. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. 2018. doi.org/10.1210/jc.2018-00229